PRELUDE THERAPEUTICS INC's ticker is PRLD and the CUSIP is 74065P101. A total of 54 filers reported holding PRELUDE THERAPEUTICS INC in Q3 2022. The put-call ratio across all filers is - and the average weighting 0.0%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q2 2023 | $12,961,196 | 0.0% | 2,273,894 | 0.0% | 0.01% | 0.0% |
| Q1 2023 | $12,961,196 | -8.1% | 2,273,894 | -2.7% | 0.01% | -14.3% |
| Q4 2022 | $14,109,102 | -99.9% | 2,335,944 | -2.8% | 0.01% | -22.2% |
| Q3 2022 | $15,881,153,000 | +25.7% | 2,402,595 | -0.7% | 0.01% | +28.6% |
| Q2 2022 | $12,635,151,000 | -24.4% | 2,420,527 | -0.1% | 0.01% | 0.0% |
| Q1 2022 | $16,714,056,000 | -11.3% | 2,422,327 | +60.0% | 0.01% | 0.0% |
| Q4 2021 | $18,845,391,000 | -59.3% | 1,513,686 | +2.0% | 0.01% | -63.2% |
| Q3 2021 | $46,353,719,000 | +25.7% | 1,483,319 | +15.2% | 0.02% | +18.8% |
| Q2 2021 | $36,867,853,000 | +32.3% | 1,287,735 | +100.3% | 0.02% | +33.3% |
| Q1 2021 | $27,860,280,000 | -24.5% | 642,979 | +24.6% | 0.01% | -29.4% |
| Q4 2020 | $36,921,875,000 | +68.7% | 516,029 | -29.0% | 0.02% | +41.7% |
| Q3 2020 | $21,888,330,000 | – | 726,463 | – | 0.01% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Orbimed Advisors | 10,909,256 | $33,709,601 | 0.72% |
| Boxer Capital, LLC | 2,495,018 | $7,709,606 | 0.41% |
| Sio Capital Management, LLC | 350,000 | $1,081,500 | 0.34% |
| Baker Brothers Advisors | 10,123,824 | $31,282,616 | 0.18% |
| EcoR1 Capital, LLC | 1,157,452 | $3,576,527 | 0.12% |
| GSA CAPITAL PARTNERS LLP | 70,583 | $218 | 0.02% |
| Pale Fire Capital SE | 30,781 | $95,113 | 0.01% |
| Woodline Partners LP | 200,000 | $618,000 | 0.01% |
| JACOBS LEVY EQUITY MANAGEMENT, INC | 143,957 | $444,827 | 0.00% |
| EXCHANGE TRADED CONCEPTS, LLC | 32,907 | $101,683 | 0.00% |